G1

RTP oncology firm G1 strikes 3rd licensing deal in 3 months, latest one being worth up to $170M

Posted by WRAL TechWire | Aug 3, 2020

G1 Therapeutics has struck another development deal for its oncology portfolio, the latest one announced Monday being worth as much as $170 million plus future royalties.

Tech Today: BioCryst raises $115M, grants stock to 5 hires; G1 secures $100M; Charles & Covard new CEO; Akoustis names sales exec

Posted by WRAL TechWire | Jun 2, 2020

The COVID-19 pandemic is not stopping many NC companies from making news with BioCryst, G1 Therapeutics, Charles & Covard and Akoustis among those generating headlines. Here’s what’s happening.